Business
AIM Rule 17 Schedule 2(g) Update
AIM Rule 17 Schedule 2(g) Update.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \n \n \n 15 March 2023 \n \n \n \n \n \n \n \n \n \n Oxford BioDynamics Plc\n \n \n \n \n \n \n \n \n \n (\n \n \"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \n \n AIM Rule 17 Schedule 2(g) Update\n \n \n Oxford BioDynamics Plc (AIM: OBD), \n a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch\n ® \n 3D genomics platform\n , announces the following information is being disclosed pursuant to Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for Companies:\n \n \n \n David Holbrook, Non-Executive Director\n \n \n \n \n \n \n David Holbrook was appointed a director of Eykona Medical Limited (\"Eykona\") on 17 September 2010. On 5 December 2013, Eykona entered a creditors voluntary liquidation and was dissolved on 14 May 2018 with a deficiency to unsecured creditors of approximately £1.79 million.\n \n \n \n \n \n \n \n \n For further details please contact:\n \n \n \n \n \n \n \n \n \n \n \n Oxford BioDynamics Plc\n \n \n \n Jon Burrows, CEO\n \n \n Paul Stockdale, CFO\n \n \n \n \n \n \n \n +44 (0)1865 518910\n \n \n \n \n \n \n \n Shore Capital\n \n \n \n \n Nominated Adviser and Broker\n \n \n \n Stephane Auton\n \n \n John More\n \n \n \n \n \n \n \n +44 (0)20 7408 4090\n \n \n \n \n \n \n Instinctif Partners\n \n \n \n \n Tel: +44 (0)20 7457 2020\n \n \n \n \n \n \n Melanie Toyne-Sewell / Rozi Morris\n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n Notes for Editors\n \n \n \n \n \n \n \n \n \n About Oxford BioDynamics Plc\n \n \n \n Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.\n \n \n Its flagship product is \n \n \n EpiSwitch® CiRT\n \n \n (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.\n \n \n In March 2021, the Company launched its first commercial prognostic test, \n \n \n EpiSwitch\n \n \n ®\n \n \n \n \n \n CST\n \n \n (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and b...